Commonwealth Equity Services
SYRE icon

Commonwealth Equity Services’s Spyre Therapeutics SYRE Stock Holding History

Commonwealth Equity Services’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-400
Closed -$46K – 3003
2020
Q1 		$46K Hold
400
– – ﹤0.01% 2694
2019
Q4 		$76K Hold
400
– – ﹤0.01% 2769
2019
Q3 		$76K Hold
400
– – ﹤0.01% 2708
2019
Q2 		$68K Buy
+400
New +$69.1K ﹤0.01% 2670

Other funds holding SYRE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Commonwealth Equity Services's SYRE Position: Q2 2020 in Review

Commonwealth Equity Services sold out of Spyre Therapeutics (SYRE) in Q2 2020, closing a stake of 400 shares — an estimated $46K sold.

Commonwealth Equity Services first reported a position in SYRE in Q2 2019 and held it in 4 quarters. The position peaked at $76K in Q4 2019. 87 funds tracked by Wall St. Rank hold SYRE as of Q2 2020.

  • Commonwealth Equity Services reported no remaining Spyre Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Commonwealth Equity Services sold 400 Spyre Therapeutics shares in Q2 2020, an estimated $46K.
  • Commonwealth Equity Services first reported a position in Spyre Therapeutics in Q2 2019 and held it in 4 quarters.
  • Commonwealth Equity Services's Spyre Therapeutics position peaked at $76K in Q4 2019.
  • 87 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2020.

Based on Commonwealth Equity Services's 13F filing for Q2 2020, filed 12 Aug 2020.